Praziquantel resistance

Expert Opinion on Drug Discovery

Volumn 2, Issue SUPPL. 1, 2007, Pages

  Botros, Sanaa S ^a   Bennett, James L ^b  

^a THEODOR BILHARZ RESEARCH INSTITUTE   (Egypt)

^b Academy of Medical Sciences and Technology Sudan   (Sudan)

Author keywords

Praziquantel; Resistance; Schistosomiasis

Indexed keywords

10 [2 (DIETHYLAMINO)ETHYL] 9(10H) ACRIDINONE (2 THIAZOLIDINYLIDENE)HYDRAZONE; HYCANTHONE; OXAMNIQUINE; PRAZIQUANTEL;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG MONITORING; DRUG RESPONSE; DRUG TREATMENT FAILURE; FOLLOW UP; GENOTYPE; HUMAN; IN VIVO STUDY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SCHISTOSOMIASIS; SINGLE DRUG DOSE;

EID: 35349009928     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.S1.S35     Document Type: Article

References (38)

1. WEBBE G, JAMES C: A comparison of the susceptibility to praziquantel of Schistosoma haematobium, S. japonicum, S. mansoni, S. intercalatum, and S. mattheei in hamsters. Z Parasitenkd (1977) 52:169-177.
2. GÖNNERT R, ANDREWS P: Praziquantel, a new broad-spectrum antischistosomal agent. Z Parasitenkd (1977) 52:129-150.
3. SABAH AA, FLETCHER C, WEBBE G, DOENHOFF MJ: Schistosoma mansoni: chemotherapy of infections of different ages. Exp. Parasitol. (1986) 61:249-303.
4. XIAO SH, CATTO BA, WEBSTER LT: Effects of praziquantel on different developmental stages of Schistosoma mansoni in vivo and in vitro. J. Infect. Dis. (1985) 151:1130-1137.
5. PICA-MATTOCCIA L, CIOLI D: Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int. J. Parasitol. (2004) 34:527-533.
6. DAVIS A, BILES JE, ULRICH AM: Initial experiences with praziquantel in the treatment of human infections due to Schistosoma haematobium. Bull. World Health Organ. (1979) 57:773-779.
7. KATZ N, ROCHA R, CHAVES A: Preliminary trials with praziquantel in human infections due to Schistosoma mansoni. Bull. World Health Organ. (1979) 57:781-785.
8. ISHIZAKI T, KAMO E, BOEHME E: Double-blind studies of tolerance to peaziquantel in Japanese patients with Schistosoma japonicum infections. Bull. World Health Organ. (1979) 57:787-791.
9. FENWICK A, SAVIOLI L, ENGELS D, ROBERT BERGQUIST NR, TODD MH: Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol. (2003) 19(11):509-515.
10. KUSEL J, HAGAN P: Praziquantel - its use, cost and possible development of resistance. Parasitol. Today (1999) 15:352-354.
11. EL-KHOBY T, GALAL N, FENWICK A: The USAID/Government of Egypt's schistosomiasis research project (SRP). Parasitol. Today (1998) 14:92-96.
12. FALLON PG, DOENHOFF MJ: Drug resistant schistosomiasts: resistance to praziquantel and oxamniquine induced Schistosoma mansoni in mice is drug specific. Am. J. Trop. Med. Hyg. (1994) 51(1):83-88.
13. CHIDIAC C, BEAUCAIRE G, MOUTON Y et al.: Echecs au praziquantel dans la traitment des Bilharzioses: interet de la biopsie de muquese rectale et du suivi prolonge. Med. Malad. Infect. (1986) 5:380-384.
14. COLES GC, BRUCE JI, KINOTI GK et al.: The potential for drug resistance in schistosomiasis. Parasitol. Today (1987) 3:349-350.
15. BRUCE JI, DIAS LC, LIAN Y-S, COLES GC: Drug resistance in schistosomiasis: a review. Mem. Inst. Oswaldo Cruz (1987) 82(IV):143-150.
16. GRYSEELS B, STELMA FF, TALLA I et al.: Epidemiology, immunology, and chemotherapy of Schistosoma mansoni infections in a recently exposed community in Senegal. Trop. Georg. Med. (1994) 46(4 Spec. No):209-219.
17. STELMA FF, TALLA I, SOW S et al.: Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am. J. Trop. Med. Hyg. (1995) 53(2):167-170.
18. WEGNER DHG: The profile of the trematocidal compound praziquantel. Arzneimettelforschung (1984) 34:1132-1136.
19. GUISSE F, POLMAK K, STELMA FF et al.: Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal. Am. J. Trop. Med. Hyg. (1997) 56(5):511-514.
20. TCHUEM-TCHUENTE LA, SOUTHGATE VR, MBAYE A et al.: The efficacy of praziquantel against Schistosoma mansoni infection in Ndombo, Northern Senegal. Trans. R. Soc. Trop. Med. Hyg. (2001) 95:65-66.
21. FALLON PG, STURROCK RF, NIANG AC, DOENHOFF MJ: Short report: diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni. Am. J. Trop. Med. Hyg. (1995) 53(1):61-62.
22. FALLON PG, MUBARAK JS, FOOKES RE et al.: Schistosoma mansoni maturation rate and drug susceptibility of different geographic isolates. Exp. Parasitol. (1997) 86(1):29-36.
23. LIANG YS, COLES GC, DOENHOFF MJ, SOUTHGATE VR: In vitro responses of praziquantel-resistant and -susceptible Schistosoma mansoni to praziquantel. Int. J. Parasitol. (2001) 31(11):1227-1235.
24. STELMA FF, SALL S, DAFF B, SOW S, NIANG M, GRYSEELS B: Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates praziquantel are usually low. J. Infect. Dis. (1997) 176(1):304-307.
25. ISMAIL M, METWALLY A, FARGHALY A, BRUCE J, TAO LF, BENNETT JL: Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am. J. Trop. Med. Hyg. (1996) 55:214-218.
26. ISAMIL M, BOTROS S, METWALLY A et al.: Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am. J. Trop. Med. Hyg. (1999) 60:932-935.
27. PICA-MATTOCCIA L, DE SOUZA DIAS LC, MORONI R, CIOLI D: Schistosoma mansoni: genetic complementation analysis shows that two independent hycanthone/oxamniquine resistant strains are mutated in the same gene. Exp. Parasitol. (1993) 77:445-449.
28. WILLIAM S, BOTROS S, ISMAIL M, FARGHALLY A, DAY TA, BENNETT JL: Praziquantel-induced tegumental damage in vitro is diminished in schistosomes derived from praziquantel-resistant infections. Parasitology (2001) 122:63-66.
29. + uptake as possible in vitro correlates to in vivo ED50 determination. Int. J. Parasitol. (2004) 34:971-977.
30. KING CH, MUCHIRI EM, OUMA JH: Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya. Emerg. Infect. Dis. (2000) 6(6):585-594.
31. CIOLI D, BOTROS S, WHEATCROFT-FRANCKLOW K et al.: Determination of ED50 values for praziquantel in praziquantel-resistant and susceptible Schistosoma mansoni isolates. Int. J. Parasitol. (2004) 34(8):979-987.
32. WORLD HEALTH ORGANIZATION: Schistosomiasis in low transmission areas: control strategies and criteria for elimination. Report of the WHO informal consultation. WHO/CDS/CPE/2001.1.London (2000).
33. BOTROS S, SAYED H, AMER N, EL-GHANNAM M, BENNETT JL, DAY TA: Current status of sensitivity praziquantel in a focus of potential drug resistance in Egypt. Int. J. Parasitol. (2005) 35:787-779.
34. VAN LEISHOUT L, STELMA FF, GUISSE F et al.: The contribution of host-related factors to low cure rates of praziquantel for the treatment of Schistosoma mansoni in Senegal. Ann. J. Trop. Med. Hyg. (1999) 61:760-765.
35. WILLIAM S, SABRA A, RAMZY F et al.: Stability and reproductive fitness of Schistosoma mansoni isolates with decreased sensitivity to praziquantel. Int. J. Parasitol. (2001) 31:1093-1100.
36. DANSO-APPIAH A, DE VLAS SJ: Interpreting low praziquantel cure rates of Schistosoma mansoni in Senegal. Trends Parasitol. (2002) 18(3): 125-129.
37. SULAIMAN SM, ALI HM, HOMEIDA MM, BENNETT JL: Efficacy of a new Hoffman-La Roche compound (Ro-15-5458) against Schistosoma mansoni (Gezira strain, Sudan) in vervet monkeys (Cercopithecus aethiops). Trop. Med. Parasitol. (1989) 40:335-336.
38. PEREIRA LH, COELHO PM, COSTA JO, DE MELLO RT: Activity of 9-acridanone-hydrazone drugs detected at the pre-postural phase, in the experimental Schistosomiasis mansoni. Mem. Inst. Oswaldo Cruz (1995) 90:425-428.